Affordable Diabetes Care Arrives in SA with Novo Nordisk

Novo Nordisk South Africa GM Sara Norcross explains the launch of the country’s only authorised copy of semaglutide, manufactured using the identical API, process and device as the originator — but at a more affordable price. We unpack what an authorised copy is, why SAHPRA registration matters, how the Acino partnership expands access, and what this means for millions of South Africans living with diabetes.